|Targets||Src | VEGFR|
|Description||TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD. It is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies.|
|Synonyms||TG 100801; TG100801; TG-100801|
ZM323881 inhibits VEGF-A, EGF and bFEF induced HUVEC cell proliferation with IC50 of 8 nM, 1.9 μM and 1.6 μM, respectively. ZM323881 (10 nM) abolishes VEGF-A-me...
LCB 03-0110 dihydrochloride is a c-Src kinase inhibitor with IC50 value of 1.3 nM. It can inhibit activation of macrophages and fibroblasts and suppress scar fo...
eCF506 is a potent and highl selective inhibitor towards Src tyrosine kinase with a 1000-fold selectivity over ABL. eCF506 inhibits SRC at subnanomolar concentr...
Regorafenib, also known as BAY 73-4506, is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds ...
Lck Inhibitor is a small-molecule inhibitor. It takes participate in the T-cell receptor (TCR) signal transduction and affects the expression of genes associate...
Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer a...
JNJ 17029259 is an selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2), blocks VEGF-stimulated mitogen-activated prot...
BFH772, a structure analogue of BAW2881, was highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM, however, lost 500-fold potency on FLK-1, FL...